Array BioPharma Inc. · Boulder, CO United States (NASDAQ: ARRY)
Key Array BioPharma Inc. Financials
| Company Type | Public -(NASDAQ: ARRY) Headquarters |
|---|---|
| Fiscal Year-End | June |
| 2011 Sales (mil.) | $71.9 |
| 2011 Employees | 259 |
Array BioPharma Inc. Income Statement
| Jun 11 | Jun 10 | Jun 09 | |
| Revenue | 71.9 | 53.9 | 25.0 |
| Cost of Goods Sold | 28.9 | 28.3 | 19.9 |
| Gross Profit | 43.0 | 25.6 | 5.1 |
| Gross Profit Margin | 59.8% | 47.4% | 20.5% |
| SG&A Expense | 16.3 | 17.1 | 18.0 |
| Depreciation & Amortization | 7.6 | 6.3 | 6.6 |
| Operating Income | (36.8) | (64.1) | (102.5) |
| Operating Margin | -51.1% | -118.9% | -410.1% |
| Nonoperating Income | (4.4) | 1.3 | (17.7) |
| Nonoperating Expenses | (15.1) | (14.9) | (7.9) |
| Income Before Taxes | (56.3) | (77.6) | (128.1) |
| Income Taxes | (0.3) | ||
| Net Income After Taxes | (56.3) | (77.6) | (127.8) |
| Continuing Operations | (56.3) | (77.6) | (127.8) |
| Discontinued Operations | -- | -- | -- |
| Total Operations | (56.3) | (77.6) | (127.8) |
| Total Net Income | (56.3) | (77.6) | (127.8) |
| Net Profit Margin | -78.3% | -144.1% | -511.6% |
| Diluted EPS from Total Net Income | (1.02) | (1.55) | (2.67) |
| Dividends per Share | -- | -- | -- |
All amounts in millions of US Dollars except per share amounts.
Array BioPharma Inc. Balance Sheet
| Assets | Jun 11 | Jun 10 | Jun 09 |
| Current Assets | |||
| Cash | 48.1 | 32.8 | 33.2 |
| Net Receivables | -- | -- | -- |
| Inventories | -- | -- | -- |
| Other Current Assets | 22.5 | 84.5 | 11.7 |
| Total Current Assets | 70.6 | 117.3 | 44.9 |
| Net Fixed Assets | 15.7 | 21.4 | 26.5 |
| Other Noncurrent Assets | 3.1 | 20.5 | 23.6 |
| Total Assets | 89.4 | 159.2 | 95.1 |
| Liabilities | Jun 11 | Jun 10 | Jun 09 |
| Current Liabilities | |||
| Accounts Payable | 4.5 | 5.6 | 6.5 |
| Short-Term Debt | 0.2 | 0.0 | 15.0 |
| Other Current Liabilities | 65.2 | 72.3 | 28.8 |
| Total Current Liabilities | 69.8 | 77.9 | 50.3 |
| Long-Term Debt | 91.4 | 112.8 | 68.2 |
| Other Noncurrent Liabilities | 59.0 | 85.1 | 50.3 |
| Total Liabilities | 220.2 | 275.9 | 168.8 |
| Shareholder's Equity | |||
| Preferred Stock Equity | 30.0 | 0.0 | 0.0 |
| Common Stock Equity | (160.9) | (116.7) | (73.7) |
| Total Equity | (130.9) | (116.7) | (73.7) |
| Shares Outstanding (thou.) | 57,020.0 | 53,224.2 | 48,125.8 |
All amounts in millions of US Dollars except per share amounts.
Array BioPharma Inc. Cash Flow Statement
| Jun 11 | Jun 10 | Jun 09 | |
| Net Operating Cash Flow | (66) | 18 | (93) |
| Net Investing Cash Flow | 74.1 | (69.1) | 29.0 |
| Net Financing Cash Flow | 7.1 | 51.1 | 40.7 |
| Net Change in Cash | 15.3 | (0.4) | (23.2) |
| Depreciation & Amortization | 7.6 | 6.3 | 6.6 |
| Capital Expenditures | (1.9) | (1.3) | (2.9) |
| Cash Dividends Paid |
All amounts in millions of US Dollars except per share amounts.